Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

This biotech powerhouse could maintain its strength for the long term.

This player's pipeline should keep growth going over the long run.

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Cory has been a professional trader for two decades. In addition to trading and investing he's widely published and coaches individual clients on the finer points of gaining an edge in the market.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

Laffont's new addition may represent an exciting recovery story.